Qfix Revenue and Competitors

Avondale, PA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Qfix's estimated annual revenue is currently $24.1M per year.(i)
  • Qfix's estimated revenue per employee is $251,000

Employee Data

  • Qfix has 96 Employees.(i)
  • Qfix grew their employee count by -20% last year.

Qfix's People

NameTitleEmail/Phone
1
VP, Research & DevelopmentReveal Email/Phone
2
Director Strategic Research and DevelopmentReveal Email/Phone
3
Director Manufacturing Engineering & FacilitiesReveal Email/Phone
4
Director, ITReveal Email/Phone
5
Director FinanceReveal Email/Phone
6
Safety Health and Environment ManagerReveal Email/Phone
7
Regional Sales ManagerReveal Email/Phone
8
Kaizen Office & Product Labeling ManagerReveal Email/Phone
9
Planning and Logistics ManagerReveal Email/Phone
10
Value Stream ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$73.5M29312%N/AN/A
#2
$7M28-10%N/AN/A
#3
$37.9M15113%N/AN/A
#4
$2.1M17-78%$64.3MN/A
#5
$9.3M37-10%N/AN/A
#6
$56.2M1790%N/AN/A
#7
$38.9M155-1%N/AN/A
#8
$22.1M885%N/AN/A
#9
$22.1M889%N/AN/A
#10
$33.4M13310%N/AN/A
Add Company

What Is Qfix?

Qfix is an innovative medical device company focused on discovering, developing and commercializing technology-driven solutions for radiotherapy patient positioning. Our focus is to foster a deep engagement with medical professionals. We make it our business to listen closely to clinical needs so that together we can advance precise positioning solutions for cancer treatment. Over 40 years ago, we invented the first low temperature thermoplastic, Aquaplast RT, which is now the most recognized brand of thermoplastics in the world. Building on this innovation, we developed Fibreplast, a Kevlar® reinforced version of Aquaplast RT, enabling us to provide the most rigid thermoplastic available. Both Aquaplast RT and Fibreplast are used around the world to create rigid masks and shells. In addition to thermoplastics, Qfix developed a wide variety of patient positioning devices to provide tremendous flexibility in treatment options. The revolutionary kVue IGRT Couch Top design allows customization for individual patient needs through the most advanced array of treatment solutions for head and neck, breast, lung, prostate and other disease sites. No other product offers a more complete and advanced system for both kV imaging and MV treatment. For example the kVue with DoseMax insert, at 2mm water equivalent thickness, offers a unique combination of rigidity and ultra-low attenuation. - See more at: http://qfix.com/about-qfix/about-qfix.asp#sthash.wqKCiqeF.dpuf

keywords:N/A

N/A

Total Funding

96

Number of Employees

$24.1M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Qfix News

2022-04-19 - Patient Positioning Radiation Therapies Market Size, Outlook And ...

CIVCO Radiotherapy, Klarity Medical Products, CDR Systems, Elekta, Qfix, Candor Denmark, Orfit Industries, IZI Medical Products, LAP, Mizuho OSI, Smith and...

2022-04-19 - Radiotherapy Patient Positioning Devices Market Size, Outlook And ...

CIVCO Radiotherapy, CDR Systems, Elekta, Qfix, Candor Denmark, Orfit Industries, LAP, Mizuho OSI, Smith and Nephew, Blessing Cathay.

2022-04-17 - Radiotherapy Patient Positioning Devices Market Size ...

CIVCO Radiotherapy, CDR Systems, Elekta, Qfix, Candor Denmark, Orfit Industries, LAP, Mizuho OSI, Smith and Nephew, Blessing Cathay.

2022-04-17 - Patient Positioning Radiation Therapies Market Size, Outlook ...

CIVCO Radiotherapy, Klarity Medical Products, CDR Systems, Elekta, Qfix, Candor Denmark, Orfit Industries, IZI Medical Products, LAP, Mizuho OSI, Smith and...

2022-04-13 - Immobilization Products Market Size, Share, Growth 2022-2029| Key ...

Bionix Radiation Therapy; Candor ApS. Qfix; AliMed; CIVCO Radiotherapy; 3M Health Care Ltd; Orfit Industries NV; Radiation Products Design; Ambu...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35.6M1086%N/A
#2
$19.8M11338%N/A
#3
$46.3M1565%N/A
#4
$68.3M2143%N/A
#5
$72.9M3245%N/A